艾布鲁(301259) - 301259艾布鲁投资者关系管理信息20250523
2025-05-23 11:10
| | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 ☑业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观□其他() | | 参与单位名称 | 投资者网上提问 | | 及人员姓名 | | | 时间 | 年 月 日 (星期五) 下午 2025 5 23 15:00~17:00 | | | 公司通过全景网"投资者关系互动平台" | | 地点 | (https://ir.p5w.net)采用网络远程的方式召开业绩 | | | 说明会 | | | 1、总经理游建军; 2、副总经理、董事会秘书、财务负责人殷明坤; | | 上市公司接待人员 | | | 姓名 | 3、独立董事张林新; | | | 4、保荐代表人薛冰。 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了 | | 投资者关系活动主要 内容介绍 | 回复: | | | 1、公司在环保和社会责任方面有哪些具体丼措?未来是否有计划进一步强化这些方面的表 | | | 现? | | | 尊敬的投资者,您好! | | | 公司自成立以来,积极响 ...
睿智医药(300149) - 300149睿智医药业绩说明会、路演活动信息20250523
2025-05-23 11:10
证券代码:300149 证券简称:睿智医药 睿智医药科技股份有限公司投资者关系活动记录表 编号:2025-02 | 投资者关系活动 | □特定对象调研□分析师会议 | | --- | --- | | | □媒体采访■业绩说明会 | | 类别 | □新闻发布会□路演活动 | | | □现场参观 □其他 | | 参与单位名称及 | 睿智医药 年度业绩说明会采用网络远程方式进行,面向全体投资者 2024 | | 人员姓名 | | | 时间 | 年 月 日 2025 5 23 15:00-17:00 | | 地点 | 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 | | | 睿智医药董事长、首席执行官(CEO):WOO SWEE LIAN | | 上市公司接待人 | 睿智医药独立董事:张雪梅 | | 员姓名 | 睿智医药首席财务官(CFO):查胤群 | | | 睿智医药董事会秘书:许剑 | | | 1.请问公司在广州购买的一块地,有何规划? 答:尊敬的投资者,感谢您的关注!公司高度重视广州地块的战略价值, | | | 但目前该地块尚未完成政府相关移交程序,公司正积极与当地 ...
鼎龙股份(300054) - 300054鼎龙股份投资者关系管理信息20250523
2025-05-23 11:09
Financial Performance - In Q1 2025, the company achieved revenue of 824 million CNY, a year-on-year increase of 16.37% [1] - Net profit attributable to shareholders reached 141 million CNY, up 72.84% year-on-year; net profit excluding non-recurring gains was 135 million CNY, an increase of 104.84% [1] CMP Polishing Pad Business - CMP polishing pad sales revenue in Q1 2025 was 220 million CNY, reflecting a year-on-year growth of 63.14% and a quarter-on-quarter increase of 13.83% [2] - The company is the only domestic supplier mastering the entire core R&D and production process for CMP polishing pads, establishing a leading position in the domestic market [2] - Future expansion includes penetrating foreign wafer manufacturers and diversifying product offerings in silicon wafer and silicon carbide markets [2] Semiconductor Display Materials - Sales revenue for semiconductor display materials in Q1 2025 was 130 million CNY, with a year-on-year growth of 85.61% and a quarter-on-quarter increase of 8.48% [3] - The company has become a leading domestic supplier for YPI and PSPI products, with ongoing development of new OLED display materials [3] High-end Wafer Photoresist Business - The company has made significant progress in high-end wafer photoresist, achieving product development and order acquisition within three years [4] - The production line for KrF/ArF photoresist has been established, with a capacity of 30 tons per year for the first phase and 300 tons for the second phase [4] Semiconductor Packaging Materials - In Q1 2025, the company generated sales revenue of 6.29 million CNY from packaging photoresist and temporary bonding adhesives, marking a breakthrough in this business segment [5]
亿道信息(001314) - 2025年5月23日投资者关系活动记录表
2025-05-23 11:06
Group 1: Company Overview - Yidao Information is a provider of smart electronic products and solutions, focusing on product definition and R&D design [2] - The company’s main business segments include rugged smart terminals and consumer smart terminals [2] - Rugged smart terminals encompass rugged laptops, tablets, handheld devices, and various industrial control products, applied in diverse fields such as smart manufacturing and public utilities [2] Group 2: Product Categories and Revenue Distribution - In 2024, the revenue distribution for the company’s product categories is as follows: - Smart hardware products: 75.04% - Rugged smart terminals: 9.39% - XR and AIoT products: 11.58% - Other businesses: 3.99% [3] Group 3: Profit Impact Factors - The fluctuation in profits for 2024 is attributed to three main factors: 1. Transitioning from a technology consumer to a technology provider, requiring increased R&D investment [3] 2. Depreciation and amortization costs from the newly operational "Pingshan R&D and Industrialization Base" affecting profit margins [3] 3. Enhanced internationalization efforts and brand optimization to improve market penetration and competitiveness [3] Group 4: Future Strategy - The company aims to continue driving innovation through R&D, focusing on core business operations to enhance sustainable development and improve operational performance [3]
江波龙(301308) - 2025年5月19日-21日投资者关系活动记录表
2025-05-23 11:06
深圳市江波龙电子股份有限公司 投资者关系活动记录表 编号:2025-010 投资者关系活动 类别 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观√电话会议 □其他 参与单位名称及 人员姓名 诺安基金、银华基金、东方财富证券、太保资产、东吴证券、 长江资管 时间 2025 年 5 月 19 日 (周一)下午 13:30-14:30 2025 年 5 月 20 日 (周二)下午 13:30-15:00 2025 年 5 月 20 日 (周二)下午 15:30-17:00 2025 年 5 月 21 日 (周三)上午 10:00-11:00 地点 深圳市前海深港合作区南山街道听海大道 5059 号鸿荣源前 海金融中心二期 B 座 2301 上市公司接待人 员姓名 副总经理、董事会秘书许刚翎 投资者关系经理黄琦 投资者关系资深主管苏阳春 | | 1、如何看待 2025 年存储价格走势? | | | --- | --- | --- | | | 答:展望 2025 年,云服务提供商对 AI 硬件的持续投资, | | | | 将推动对高性能计算和存储硬件的需求,服务器领域的高 ...
兴蓉环境(000598) - 2025年5月23日投资者关系活动记录表
2025-05-23 11:04
Group 1: Water Supply and Wastewater Projects - The company is currently constructing several water supply and wastewater projects, including Chengdu Water Plant Phase III (remaining capacity of 400,000 tons/day), Xiwayan Reclaimed Water Plant, and the second phase of Chengdu's Fifth and Sixth Reclaimed Water Plants, which are in debugging or trial operation stages [2][3]. Group 2: Waste Incineration Power Generation Projects - The Chengdu Wanxing Environmental Power Plant Phase III is under construction, with a household waste processing capacity of 800 tons/day, sludge co-processing capacity of 5,100 tons/day, and kitchen waste processing capacity of 800 tons/day, expected to be operational by 2026 [3]. Group 3: Accounts Receivable Management - As of the end of 2024, the company's accounts receivable balance is approximately 4 billion yuan, reflecting an increase due to market expansion. The company emphasizes accounts receivable management and has integrated collection efforts into performance assessments [3]. Group 4: Market Expansion Strategy - The company aims to be a national water and environmental service provider, focusing on expanding its market presence in Chengdu and surrounding areas while actively exploring resource integration and niche markets nationwide [3]. Group 5: Capital Expenditure and Dividend Policy - The company has significant capital expenditures due to multiple ongoing water supply and waste projects, which are expected to be operational within 1-2 years, leading to a gradual decrease in capital spending. The company is committed to increasing cash dividend ratios as major projects come online and generate capacity [3].
国际实业(000159) - 000159国际实业投资者关系管理信息20250523
2025-05-23 11:02
闵总您好,1.公司 2025 年制造业方面当前在手订单充裕, 产销量与去年相比呈增长态势。2.公司收购新疆怡宝矿业资源勘 查开发有限责任公司股权事项正在进行中,公司将严格按照深圳 证券交易所的有关规定及时履行信息披露义务。感谢您的关注。 4、收购铜矿情况如何 公司转型有何进展 尊敬的投资者您好,公司收购新疆怡宝矿业资源勘查开发有 限责任公司股权事项正在进行中,公司将严格按照深圳证券交易 所的有关规定及时履行信息披露义务。感谢您对公司的关注。 5、矿产收购协议怎么样了 证券代码:000159 证券简称:国际实业 新疆国际实业股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研□分析师会议 | | --- | --- | | 类别 | □媒体采访√业绩说明会 | | | □新闻发布会□路演活动 | | | □现场参观 | | | □其他(请文字说明其他活动内容) | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日 (周五) 下午 2025 5 23 15:00~18:00 | | 地点 | 公司通过全景网"投资者关系互动平台"(https://ir. ...
舒泰神(300204) - 300204舒泰神投资者关系管理信息20250523(1)
2025-05-23 11:02
舒泰神(北京)生物制药股份有限公司 证券代码:300204 证券简称:舒泰神 投资者关系活动记录表 编号:2025-002 | 投资者关系活动 | ■特定对象调研□分析师会议 | | | | | | --- | --- | --- | --- | --- | --- | | 类别 | □媒体采访□业绩说明会 | | | | | | | □新闻发布会□路演活动 | | | | | | | □现场参观 | | | | | | | □其他 | | | | | | 参与单位名称 | 国泰海通等 | | | | | | 时间 | 日 2025 11:30-12:30 | 年 | 05 | 月 | 23 | | 地点 | 公司会议室 | | | | | | 上市公司接待人 | 董事长周志文先生 | | | | | | 员姓名 | 董事会秘书、副总经理于茂荣先生 | | | | | | | 证券事务代表蔡晗先生 | | | | | | 投资者关系活动 | 投资者互动问答 | | | | | | 主要内容介绍 | | | | | | | 附件清单 | 调研纪要 | | | | | | 日期 | 2025 日 | 年 | 05 ...
舒泰神(300204) - 300204舒泰神投资者关系管理信息20250523(2)
2025-05-23 11:02
舒泰神(北京)生物制药股份有限公司接待投资者调研纪要 形式:线下调研 参会单位:国泰海通等 接待人:董事长周志文先生 董事会秘书、副总经理于茂荣先生 证券事务代表蔡晗先生 舒泰神调研纪要 时间:2025 年 05 月 23 日 11:30-12:30 舒泰神(北京)生物制药股份有限公司接待投资者调研纪要 生产许可证是取得了 B 证,项目进度在尽快推进,此前子公司贝捷泰的融资有 助于公司的长期经营发展。 3、请问公司 STSA-1002 注射液项目目前研发进展情况? 回答:STSA-1002 注射液项目在急性呼吸窘迫综合征适应症的 II 期临床试 验正在推进,已处于收尾阶段,希望可以取得预期的临床进展。STSA-1002 注射 液由公司自主研发,已在国内和国际申请发明专利,有全球权益。 一、投资者互动问答 1、请问公司 STSP-0601 项目目前研发及注册进展情况? 回答:注射用 STSP-0601("波米泰酶α ")用于伴抑制物血友病 A 或 B 患者出血按需治疗已取得 IIb 期临床研究总结报告,2025 年 01 月已公告 的 IIb 结果已达到主要有效性终点。目前正在开展 III 期临床研究,已完成 ...